Slomovitz, B. M., Monk, B. J., Tewari, K. S., Cloven, N., Farolfi, A., Ferrero, A., Cibula, D., Dubot, C., Barraclough, L., Fariñas-Madrid, L., Casarini, I., Melo, A. C. D., Mejia, F. C., Gupta, S., Lee, J., Hasegawa, K., Yu, Z., Tekin, C., Desai, V., Gorp, T. V. (2026). TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase 3, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps5628